A thermally modulating inhalable medicament delivery device may deliver an inhalable medicament as an aerosol, vapor, or partial aerosol and partial vapor mixture. The inhalable medicament may be delivered to a target in a subject. Described herein are devices, systems, and methods for delivering an inhalable medicament to a subject.

A thermally modulating inhalable medicament delivery device may deliver an inhalable medicament as an aerosol, vapor, or partial aerosol and partial vapor mixture. The inhalable medicament may be delivered to a target in a subject. Described herein are devices, systems, and methods for delivering an inhalable medicament to a subject.

An apparatus for delivering a therapeutic agent may be associated with a cap for a bottle that contains a prescription for a drug to which the therapeutic agent corresponds. When the prescription bottle contains an opioid, the therapeutic agent may comprise a substance that counteracts the effects of the opioid. The apparatus may include a nozzle that facilitates nasal administration of the therapeutic agent. The apparatus may be capable of attaching to a cap for a prescription bottle, or the apparatus may have a configuration that enables it to serve as the cap for the prescription bottle.

A nose-to-brain drug delivery device is provided. The nose-to-brain drug delivery device includes a freeze-dried drug container for storing a freeze-dried drug, a restoring solvent container for storing a solvent for thawing the freeze-dried drug, a membrane for preventing the freeze-dried drug from being mixed with the solvent, and a compressor for providing a driving force. The membrane is opened by the driving force of the compressor to mix the freeze-dried drug with the solvent, thereby thawing the freeze-dried drug, and the thawed drug is sprayed by the driving force of the compressor.

Formulations and methods for the preventative treatment of incidental opioid overdose comprising the intranasal (IN) administration of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.

A vaporizing assembly for an aerosol-generating system may comprise a delivery device and a heater assembly. The heater assembly may comprise a heat resistive substrate and a heating element. The delivery device is configured to deliver an aerosol-forming substrate to at least a surface of the heat resistive substrate, wherein the heating element is isolated or separated from the aerosol-forming substrate by the heat resistive substrate. The present disclosure is also directed to a method for generating an aerosol.

There is provided an aerosolizable gel comprising (a) an active agent; (b) one or more gel forming materials, wherein the one or more gel forming material is at least one phyllosilicate; (c) an aerosol forming material selected from glycerol, propylene glycol and mixtures thereof; and (d) water.

A medication delivery device involves an ampule having a receptacle base secured to a tab-shaped cap. The exterior surface between the base and cap is scored to permit a user to twist the cap in a first direction thereby severing the cap from the base and permitting medication secured within the base to be accessed. Adjacent the cap on an interior of the ampule is a unidirectional valve which moderates the ejection of fluid into at least two (2) doses. An exterior portion of the base has a surface suitable for any desired indicia.

An electronic smoking article includes an aerosol generator and a mouth end insert. The mouth end insert includes a mechanical aerosol converter surface having the capacity to improve characteristics of aerosol produced by the aerosol generator, including sensory attributes.

A liquid human milk supplement comprising at least the amino acids leucine, isoleucine, valine, lysine, methionine, threonine, phenylalanine, histidine, and tryptophan, and at least one free semi-essential amino acid selected from tyrosine, cysteine, glycine, glutamic acid and arginine, wherein the weight ratio of the amount of the essential amino acids and the semi-essential amino acids to the total amount of free amino acids is at least 80%. The supplement is particularly suitable for feeding infants and low-birth-weight infants. A single-dose and a multi-dose dispenser comprise the supplement in suitable and adjustable volumes. The dispensers can be used for administration of the liquid human milk supplement to an infant during feeding.